Targeting treatment: Predictive and prognostic role of autoantibodies in RA


Sponsored by Bristol-Myers Squibb Australia

A symposium at EULAR 2016, held in London in June, addressed the targeting of unmet needs in autoantibody-driven inflammatory diseases, with a focus on seropositive rheumatoid arthritis (RA). The symposium, sponsored by Bristol-Myers Squibb, was chaired by Professor Paul Emery from the University of Leeds, UK. Professor Tom Huizinga, from the Department of Rheumatology at ...


Already a member? Login to keep reading


OR
© 2017 the limbic